KRAS mutation is a significant predictor of metastasis and survival in pancreatic cancer, study shows

Adding a lower cutoff value for CA19-9 may identify additional high-risk cases of pancreatic cancer

A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic cancer who had high-risk disease despite having low CA19-9 levels because of a genetic variation that impairs their ability to produce this biomarker.

May 29, 2026

Vol.52 No.21

Drugs & Targets

FDA grants Orphan Drug designation to oxaliplatin delivered via RenovoCath catheter for pancreatic cancer

RenovoRx Inc. received an Orphan Drug Designation of oxaliplatin for the treatment of pancreatic cancer delivered via RenovoCath device.

May 29, 2026

Vol.52 No.21

Clinical Roundup

Electric jolt technique offers possible avenue for early detection of pancreatic cancer, OHSU-led study finds

Scientists at Oregon Health & Science University have developed a technique using an electronic jolt and nanoparticles to reveal the telltale signal of an insidious form of cancer. The technique offers a new way to detect early signs of pancreatic cancer—a particularly deadly type of cancer because it isn’t detected until it’s progressed to later stages that are difficult to treat effectively. The new method would involve a simple blood draw among people who are considered higher risk due to family history or other factors.

May 08, 2026

Vol.52 No.18

Clinical Roundup

Mayo and Stanford researchers develop first blood test to map tumor “neighborhoods,” improving prediction of therapy response

A blood test could map the complex ecosystem surrounding cancer cells, offering a more accurate way to predict which patients will benefit from immunotherapy, according to researchers at Mayo Clinic and Stanford Medicine. The test they developed could help guide treatment decisions across multiple cancer types and treatments.

May 08, 2026

Vol.52 No.18

Drugs & Targets

FDA permits expanded access for investigational pancreatic cancer drug daraxonrasib

FDA has issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol for its experimental pancreatic cancer drug, daraxonrasib, a RAS inhibitor.

May 08, 2026

Vol.52 No.18

By Claire Marie Porter

Clinical Roundup

Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds

A Mayo Clinic has developed an artificial intelligence model that can help specialists detect pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis. It identifies subtle signs of disease before tumors are visible, when curative treatment may still be possible.

May 01, 2026

Vol.52 No.17

KRAS mutation is a significant predictor of metastasis and survival in pancreatic cancer, study shows

YOU MAY BE INTERESTED IN

Adding a lower cutoff value for CA19-9 may identify additional high-risk cases of pancreatic cancer

FDA grants Orphan Drug designation to oxaliplatin delivered via RenovoCath catheter for pancreatic cancer

Electric jolt technique offers possible avenue for early detection of pancreatic cancer, OHSU-led study finds

Mayo and Stanford researchers develop first blood test to map tumor “neighborhoods,” improving prediction of therapy response

FDA permits expanded access for investigational pancreatic cancer drug daraxonrasib

Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds

Renew today!

Subscriber content

Never miss an issue!

Login